Published in Leukemia on March 08, 2007
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res (2012) 1.75
Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells (2008) 1.46
CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. Blood (2014) 1.42
The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia (2009) 1.33
Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med (2009) 1.31
Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med (2008) 1.27
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood (2009) 1.16
Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol (2010) 1.13
Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med (2013) 1.11
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene (2009) 1.10
Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res (2011) 1.09
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood (2009) 1.08
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells (2011) 1.07
Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res (2011) 1.06
Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. J Bone Miner Res (2012) 1.03
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. Prostate (2008) 1.03
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer (2010) 1.02
Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer (2010) 1.02
Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol (2009) 1.00
Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS One (2013) 0.99
A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer (2007) 0.98
Deterministic and stochastic approaches in the clinical application of mesenchymal stromal cells (MSCs). Front Cell Dev Biol (2014) 0.98
Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica (2013) 0.97
Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche? Blood Cancer J (2012) 0.96
Tumor-host cell interactions in the bone disease of myeloma. Bone (2010) 0.96
Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood (2013) 0.95
Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration. Blood (2010) 0.93
Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma. PLoS One (2012) 0.93
Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma (2010) 0.93
Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood (2014) 0.93
Mesenchymal stem cell secretome and regenerative therapy after cancer. Biochimie (2013) 0.93
Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. PLoS One (2013) 0.92
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacol Sin (2013) 0.91
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz) (2008) 0.90
Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms. Biomark Res (2013) 0.89
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn (2010) 0.87
Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications. Clin Cancer Res (2007) 0.87
Targeted therapy for HM1.24 (CD317) on multiple myeloma cells. Biomed Res Int (2014) 0.85
Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. Blood (2010) 0.85
The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell. Cancer Microenviron (2010) 0.85
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One (2012) 0.85
Biological, functional and genetic characterization of bone marrow-derived mesenchymal stromal cells from pediatric patients affected by acute lymphoblastic leukemia. PLoS One (2013) 0.85
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma. J Hematol Oncol (2015) 0.85
unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance? J Bone Miner Res (2014) 0.84
Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone (2015) 0.83
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget (2014) 0.83
Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention. Blood Rev (2013) 0.82
Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma. Leukemia (2016) 0.81
Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget (2016) 0.81
Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World J Stem Cells (2014) 0.81
Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol (2011) 0.81
Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease. Haematologica (2014) 0.81
The role of CCN family genes in haematological malignancies. J Cell Commun Signal (2015) 0.81
Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region. BMC Cancer (2015) 0.80
The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy. PLoS One (2014) 0.80
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? Oncotarget (2012) 0.80
A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression. Stem Cells Dev (2015) 0.78
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway. Cancer Biol Ther (2014) 0.78
The role of growth differentiation factor 15 in the pathogenesis of primary myelofibrosis. Cancer Med (2015) 0.78
CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway. Biochim Biophys Acta (2014) 0.77
Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth. J Cancer Res Clin Oncol (2012) 0.77
Isolation, characterization, and transplantation of bone marrow-derived cell components with hematopoietic stem cell niche properties. Stem Cells Dev (2013) 0.77
SDF-1α stiffens myeloma bone marrow mesenchymal stromal cells through the activation of RhoA-ROCK-Myosin II. Int J Cancer (2014) 0.77
Cx43 expressed on bone marrow stromal cells plays an essential role in multiple myeloma cell survival and drug resistance. Arch Med Sci (2016) 0.77
Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease. Haematologica (2015) 0.76
Tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness. Exp Hematol (2008) 0.75
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget (2016) 0.75
Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. Vaccines (Basel) (2016) 0.75
Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia. Haematologica (2015) 0.75
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma. Cancers (Basel) (2017) 0.75
First steps to define murine amniotic fluid stem cell microenvironment. Sci Rep (2016) 0.75
Effect of The Receptor Activator of Nuclear Factor кB and RANK Ligand on In Vitro Differentiation of Cord Blood CD133(+) Hematopoietic Stem Cells to Osteoclasts. Cell J (2016) 0.75
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget (2017) 0.75
Bone marrow stromal cells show distinct gene expression patterns depending on symptomatically involved organs in multiple myeloma. Blood Cancer J (2016) 0.75
EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. Mol Cancer Res (2017) 0.75
Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway. Oncotarget (2017) 0.75
Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate. Front Bioeng Biotechnol (2017) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
The microenvironment of the tumour-host interface. Nature (2001) 9.17
Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med (2003) 7.35
Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics (2002) 5.88
Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet (2005) 4.33
An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem (2004) 4.12
The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci (2004) 3.83
Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci U S A (2000) 2.60
Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol (2003) 2.30
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood (1994) 2.10
The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem (2003) 2.09
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood (1993) 2.02
Interleukin-6 in human multiple myeloma. Blood (1995) 1.95
Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood (2003) 1.87
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood (2005) 1.85
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res (2004) 1.74
MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res (2003) 1.71
Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood (2000) 1.59
Common cancer biomarkers. Cancer Res (2006) 1.56
WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol (2004) 1.53
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene (2005) 1.44
'Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood (1991) 1.40
Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res (2005) 1.40
Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol (2002) 1.39
Expression of a novel member of the TGF-beta superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues. Cell Tissue Res (1999) 1.37
Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene (2004) 1.33
The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res (2005) 1.32
Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol (2004) 1.27
Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol (2000) 1.21
Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3). Proc Natl Acad Sci U S A (1999) 1.20
Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways. J Biol Chem (2003) 1.17
Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer (2001) 1.13
Microarray-based understanding of normal and malignant plasma cells. Immunol Rev (2006) 1.12
The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab (2000) 1.12
Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia (2005) 1.06
Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol (2003) 1.03
Novel therapies for multiple myeloma. Br J Haematol (2003) 1.02
Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies. Mol Immunol (1991) 0.99
Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases. Endocrinology (2001) 0.92
Characterization of bone marrow stromal cells from multiple myeloma. Leuk Res (1994) 0.92
Myeloma bone disease. Best Pract Res Clin Haematol (2005) 0.91
Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program (2003) 0.89
The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase. Endocrinology (2002) 0.89
Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood (1999) 0.87
Angiogenic switch in multiple myeloma. Hematology (2005) 0.87
Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein. J Biol Chem (2001) 0.86
Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol (1998) 0.85
Attraction of human monocytes by the neuropeptide secretoneurin. FEBS Lett (1993) 0.83
Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br J Haematol (1993) 0.81
Human bone marrow stroma-dependent myeloma sister cell lines MOLP-6 and MOLP-7 derived from a patient with multiple myeloma. Hum Cell (2000) 0.78
In vitro growth and osteoblastic differentiation of human bone marrow stromal cells supported by autologous plasma. Bone (2004) 0.78
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Infectivity in mouse fibroblasts of polyoma DNA integrated into plasmid pBR322 or lambdoid phage DNA. Nature (1979) 2.92
Health and race in California. Am J Public Health (1971) 2.85
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia (2009) 2.25
A role for preadipocytes as macrophage-like cells. FASEB J (1999) 2.24
A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol (1996) 2.21
An automated p-nitrophenylphosphate serum alkaline phosphatase procedure for the AutoAnalyzer. Clin Chem (1965) 2.14
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood (1994) 2.10
Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia (2003) 1.96
A non-invasive test for assessing embryo potential by gene expression profiles of human cumulus cells: a proof of concept study. Mol Hum Reprod (2008) 1.95
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet (1997) 1.94
Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation (1997) 1.90
Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood (2000) 1.87
Myeloproliferative virus, a cloned murine sarcoma virus with spleen focus-forming properties in adult mice. J Virol (1980) 1.85
Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood (1990) 1.75
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol (2000) 1.73
Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest (1989) 1.72
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis. J Exp Med (1999) 1.67
Increased percentage of CD3+, CD57+ lymphocytes in patients with rheumatoid arthritis. Correlation with duration of disease. Arthritis Rheum (1993) 1.63
Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci U S A (1997) 1.63
Fluorometry of plasma amino nitrogen, with use of fluorescamine. Clin Chem (1976) 1.61
No detectable malignant B cells in the peripheral blood of patients with multiple myeloma. Br J Haematol (1989) 1.60
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia (2010) 1.59
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood (1992) 1.55
Leuconostoc, a potential pathogen in bone marrow transplantation. Lancet (1993) 1.54
Evaluation of a new low-dose digital x-ray device: first dosimetric and clinical results in children. Pediatr Radiol (1998) 1.52
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Intern Med (1996) 1.51
Lack of capillary recruitment in the brains of awake rats during hypercapnia. J Cereb Blood Flow Metab (1989) 1.51
Mesenchymal stem cells for clinical application. Vox Sang (2009) 1.50
CD57+ T lymphocytes are derived from CD57- precursors by differentiation occurring in late immune responses. Eur J Immunol (1994) 1.49
Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ (2000) 1.49
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia (2007) 1.48
Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom (2010) 1.48
Clonal V alpha 12.1+ T cell expansions in the peripheral blood of rheumatoid arthritis patients. J Exp Med (1993) 1.47
Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol (1993) 1.47
Native human adipose stromal cells: localization, morphology and phenotype. Int J Obes (Lond) (2011) 1.46
JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol (2000) 1.45
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant (2000) 1.44
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
The cloned human DNA excision repair gene ERCC-1 fails to correct xeroderma pigmentosum complementation groups A through I. Mutat Res (1989) 1.42
Immortalization and characterization of Nijmegen Breakage syndrome fibroblasts. Mutat Res (1999) 1.40
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood (1995) 1.39
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia (2009) 1.38
Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha. Am J Hematol (1994) 1.38
A temperature-sensitive disorder in basal transcription and DNA repair in humans. Nat Genet (2001) 1.37
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia (2000) 1.35
Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood (1989) 1.35
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood (2001) 1.34
Successful long-term correction of autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency by hematopoietic stem cell transplantation. Klin Padiatr (2010) 1.34
Automated determination of serum glutamic oxaloacetic transaminase. Clin Chem (1966) 1.34
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood (1992) 1.33
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol (1998) 1.33
Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum (1990) 1.32
RPC-5 column chromatography for the isolation of DNA fragments. Methods Enzymol (1980) 1.32
C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum (1992) 1.29
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
Gene expression profile of human endometrial receptivity: comparison between natural and stimulated cycles for the same patients. Hum Reprod (2009) 1.28
Splenomegaly and solitary spleen metastasis in solid tumors. Cancer (1987) 1.28
A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood (1998) 1.27
A strong magnetic field around the supermassive black hole at the centre of the Galaxy. Nature (2013) 1.27
p53 and RAS gene mutations in multiple myeloma. Oncogene (1992) 1.24
Phage lambda DNA packaging, in vitro. J Supramol Struct (1974) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Interdependency of local capillary density, blood flow, and metabolism in rat brains. Am J Physiol (1986) 1.23
Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients. Leukemia (2012) 1.23
Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene (2006) 1.21
Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol (2000) 1.21
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood (1995) 1.20
The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol (1999) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Tracking correlations of blood pressure levels in infancy. Pediatrics (1978) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with human immunodeficiency virus. J Clin Endocrinol Metab (1990) 1.18
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia (2011) 1.17
In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction. Cancer Res (1992) 1.17
High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol (1992) 1.17
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer (2009) 1.17
Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur J Immunol (1995) 1.16
Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. Blood (1998) 1.16
Phage lambda receptor chromosomes for DNA fragments made with restriction endonuclease I of Bacillus amyloliquefaciens H. J Mol Biol (1979) 1.15
The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant (2013) 1.14
Study of a virus-induced myeloproliferative syndrome associated with tumor formation in mice. Eur J Cancer (1980) 1.14
Mutations of the p53 gene in human myeloma cell lines. Oncogene (1992) 1.13
Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood (1994) 1.13
Retinal collateral vessel formation. Invest Ophthalmol (1971) 1.13